Finerenone - Latest Advances

Therapeutic approaches in the management of chronic kidney disease: the past, the present, and the future.

Journal: Minerva medica

Published: October 06, 2025

Simultaneous estimation of finerenone and canagliflozin using HPLC: application in metabolic stability studies.

Journal: Bioanalysis

Published: September 29, 2025

The non-steroidal MR antagonist Finerenone reverses Western diet-induced kidney disease by regulating mitochondrial and lipid metabolism and inflammation.

Journal: American journal of physiology. Renal physiology

Published: September 29, 2025

Finerenone in non-diabetic CKD: an underexplored therapeutic opportunity.

Journal: Renal failure

Published: September 19, 2025

Comparing CKD populations with T1D and T2D: a perspective based on the FINE-ONE and FIDELITY populations.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: September 19, 2025

The non-steroidal MR antagonist Finerenone reverses Western diet-induced kidney disease by regulating mitochondrial and lipid metabolism and inflammation.

Journal: bioRxiv : the preprint server for biology

Published: September 15, 2025

What is established in the medical treatment of heart failure?

Journal: Innere Medizin (Heidelberg, Germany)

Published: September 12, 2025

A new heart failure indication for finerenone (Kerendia).

Journal: The Medical letter on drugs and therapeutics

Published: September 09, 2025

Clinical insights on "Finerenone in type 1 diabetes and chronic kidney disease: short-term efficacy and safety insights".

Journal: International urology and nephrology

Published: September 07, 2025

Proteins and signalling pathways targeted by dapagliflozin and finerenone: Insights from DAPA-CKD and FIGARO-DKD.

Journal: Diabetes, obesity & metabolism

Published: September 01, 2025

Combining finerenone with SGLT-2 inhibitors: building up CONFIDENCE for the treatment of diabetic kidney disease.

Journal: Expert opinion on pharmacotherapy

Published: August 25, 2025

Response by Docherty et al to Letter Regarding Article, "Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial".

Journal: Circulation

Published: August 18, 2025

Filters

Therapeutic approaches in the management of chronic kidney disease: the past, the present, and the future.

Therapeutic approaches in the management of chronic kidney disease: the past, the present, and the future.

Simultaneous estimation of finerenone and canagliflozin using HPLC: application in metabolic stability studies.

Simultaneous estimation of finerenone and canagliflozin using HPLC: application in metabolic stability studies.

The non-steroidal MR antagonist Finerenone reverses Western diet-induced kidney disease by regulating mitochondrial and lipid metabolism and inflammation.

The non-steroidal MR antagonist Finerenone reverses Western diet-induced kidney disease by regulating mitochondrial and lipid metabolism and inflammation.

Finerenone in non-diabetic CKD: an underexplored therapeutic opportunity.

Finerenone in non-diabetic CKD: an underexplored therapeutic opportunity.

Comparing CKD populations with T1D and T2D: a perspective based on the FINE-ONE and FIDELITY populations.

Comparing CKD populations with T1D and T2D: a perspective based on the FINE-ONE and FIDELITY populations.

The non-steroidal MR antagonist Finerenone reverses Western diet-induced kidney disease by regulating mitochondrial and lipid metabolism and inflammation.

The non-steroidal MR antagonist Finerenone reverses Western diet-induced kidney disease by regulating mitochondrial and lipid metabolism and inflammation.

What is established in the medical treatment of heart failure?

What is established in the medical treatment of heart failure?

A new heart failure indication for finerenone (Kerendia).

A new heart failure indication for finerenone (Kerendia).

Clinical insights on "Finerenone in type 1 diabetes and chronic kidney disease: short-term efficacy and safety insights".

Clinical insights on "Finerenone in type 1 diabetes and chronic kidney disease: short-term efficacy and safety insights".

Proteins and signalling pathways targeted by dapagliflozin and finerenone: Insights from DAPA-CKD and FIGARO-DKD.

Proteins and signalling pathways targeted by dapagliflozin and finerenone: Insights from DAPA-CKD and FIGARO-DKD.

Combining finerenone with SGLT-2 inhibitors: building up CONFIDENCE for the treatment of diabetic kidney disease.

Combining finerenone with SGLT-2 inhibitors: building up CONFIDENCE for the treatment of diabetic kidney disease.

Response by Docherty et al to Letter Regarding Article, "Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial".

Response by Docherty et al to Letter Regarding Article, "Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial".